ArticleClinical case reports2024

Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma.

Juan José Gil-Fernández et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.